Danaher Gains On $9.6 Billion Aldevron Buy For Genomic Play

By Dhirendra Tripathi

Investing.com – Danaher (NYSE:DHR) shares were up more than 4% Thursday as the company announced it will buy privately-held Aldevron for $9.6 billion in cash.

Aldevron manufactures high-quality plasmid DNA, mRNA, and proteins, serving biotechnology and pharmaceutical customers across research, clinical and commercial applications.

Danaher President and Chief Executive Officer Rainer M. Blair said the acquisition will expand the company’s capabilities in genomic medicines and help it bring more life-saving therapies and vaccines to market faster.

Aldevron will operate as a standalone operating company and brand within Danaher's life sciences segment.

Danaher expects to finance the acquisition using cash on hand and/or proceeds from the issuance of commercial paper.

Related Articles

Danaher Gains On $9.6 Billion Aldevron Buy For Genomic Play

Audi sets 2026 end date for combustion engine cars - Sueddeutsche Zeitung

Denmark stocks lower at close of trade; OMX Copenhagen 20 down 0.84%

Advertisement